Qiagen N.V. (QIA.DE)
| Previous Close | 40.24 |
| Open | 40.53 |
| Bid | 40.71 x 48300 |
| Ask | 40.73 x 51100 |
| Day's Range | 40.37 - 40.85 |
| 52 Week Range | 33.75 - 43.40 |
| Volume | |
| Avg. Volume | 421,367 |
| Market Cap | 9.108B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 127.67 |
| EPS (TTM) | 0.32 |
| Earnings Date | Nov 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 30, 2024 |
| 1y Target Est | 47.90 |
ZacksQIAGEN's TB Testing Business Gets New Exposure at Global Summit
QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.
ZacksOPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
GlobeNewswireQIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications
Portfolio expansion reinforces QIAGEN’s leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for use on EZ1 and 2 instruments designed to enhance liquid biopsy workflows for cancer research // New QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for use in downstream applicationsVenlo, the Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prim
